SANTA BARBARA, Calif., May 26, 2020
Bexson Biomedical, Inc. today announced the expansion of its Board of Directors with the addition of Itai Danovitch, MD, MBA. Dr. Danovitch is an independent director and brings extensive experience guiding innovative biopharma companies from start-up through accelerated growth.
"We are very pleased to have Dr. Danovitch as a new member of the Bexson Board. He brings a unique and valuable perspective to help guide our development strategy," said Gregg Peterson, Bexson CEO. "He his joining Bexson at a particularly exciting time, as we bring our BB106 proprietary ketamine therapy closer to clinical use, and as ketamine-based therapies in general are being developed and studied for pain, depression, PTSD and other disorders."
Dr. Danovitch is Chairman of the Department of Psychiatry and Behavioral Neurosciences at Cedars-Sinai Medical Center in Los Angeles, a veteran of multiple corporate boards, and with research focused on substance use disorders. According to Dr. Danovitch, "I'm looking forward to working with such a groundbreaking and mission driven company. It is clear that this novel ketamine formulation and innovative delivery technology are needed in a number of key therapeutic areas."
Bexson Biomedical, Inc. is a research stage company developing proprietary ketamine-based therapies for pain management and mental health disorders. Visit at: www.bexsonbiomedical.com.